Mayne Pharma Signs Five-Year Exclusive Deal With Italfarmaco

MT Newswires Live

Yesterday

Mayne Pharma Group (ASX:MYX) has entered into an exclusive five-year agreement with Italfarmaco to register, market and distribute Blissel, an ultra-low-dose vaginal gel for menopause-related vaginal atrophy, in Australia, according to a Tuesday Australian bourse filing.

Blissel is targeted for launch in fiscal 2028 through the company's existing women's health commercial team, expanding its menopause portfolio alongside NEXTSTELLIS, per the filing.

Australia's topical vaginal estrogen market is worth around AU$27 million in 2025, growing at a 16% two-year compound annual growth rate, with the company expecting Blissel to contribute to international sales, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/2667250694"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667250694\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667250694?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 08:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667250694","market":"us","top_or_hot":-1,"title":"Mayne Pharma Signs Five-Year Exclusive Deal With Italfarmaco","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MAYNF\">Mayne Pharma</a> Group (ASX:MYX) has entered into an exclusive five-year agreement with Italfarmaco to register, market and distribute Blissel, an ultra-low-dose vaginal gel for menopause-related vaginal atrophy, in Australia, according to a Tuesday Australian bourse filing.</p><p>Blissel is targeted for launch in fiscal 2028 through the company's existing women's health commercial team, expanding its menopause portfolio alongside NEXTSTELLIS, per the filing.</p><p>Australia's topical vaginal estrogen market is worth around AU$27 million in 2025, growing at a 16% two-year compound annual growth rate, with the company expecting Blissel to contribute to international sales, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mayne Pharma Signs Five-Year Exclusive Deal With Italfarmaco</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMayne Pharma Signs Five-Year Exclusive Deal With Italfarmaco\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-15 08:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MAYNF\">Mayne Pharma</a> Group (ASX:MYX) has entered into an exclusive five-year agreement with Italfarmaco to register, market and distribute Blissel, an ultra-low-dose vaginal gel for menopause-related vaginal atrophy, in Australia, according to a Tuesday Australian bourse filing.</p><p>Blissel is targeted for launch in fiscal 2028 through the company's existing women's health commercial team, expanding its menopause portfolio alongside NEXTSTELLIS, per the filing.</p><p>Australia's topical vaginal estrogen market is worth around AU$27 million in 2025, growing at a 16% two-year compound annual growth rate, with the company expecting Blissel to contribute to international sales, the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667250694","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667250694","pubTimestamp":1789432343,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mayne Pharma Group  has entered into an exclusive five-year agreement with Italfarmaco to register, market and distribute Blissel, an ultra-low-dose vaginal gel for menopause-related vaginal atrophy, in Australia, according to a Tuesday Australian bourse filing.Blissel is targeted for launch in fiscal 2028 through the company's existing women's health commercial team, expanding its menopause portfolio alongside NEXTSTELLIS, per the filing.Australia's topical vaginal estrogen market is worth around AU$27 million in 2025, growing at a 16% two-year compound annual growth rate, with the company expecting Blissel to contribute to international sales, the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","MYX.AU":"MAYNE PHARMA GROUP LTD","BK7096":"制药"},"translate_title":"Mayne Pharma 与 Italfarmaco 签署五年独家协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYX.AU":1},"content_text":"Mayne Pharma Group (ASX:MYX) has entered into an exclusive five-year agreement with Italfarmaco to register, market and distribute Blissel, an ultra-low-dose vaginal gel for menopause-related vaginal atrophy, in Australia, according to a Tuesday Australian bourse filing.Blissel is targeted for launch in fiscal 2028 through the company's existing women's health commercial team, expanding its menopause portfolio alongside NEXTSTELLIS, per the filing.Australia's topical vaginal estrogen market is worth around AU$27 million in 2025, growing at a 16% two-year compound annual growth rate, with the company expecting Blissel to contribute to international sales, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}